Literature DB >> 12243598

Patient-specific factors predictive of warfarin dosage requirements.

Randall K Absher1, M Elisabeth Moore, Mary H Parker.   

Abstract

OBJECTIVE: To identify patient-specific factors predictive of maintenance warfarin dosage requirements >5 mg/d.
METHODS: One hundred forty-six adults taking warfarin were identified from a community hospital and an outpatient anticoagulation clinic. Patient demographics and data on warfarin doses, laboratory results, and medication use were obtained by abstracting patient records. Estimates of vitamin K intake were obtained using a questionnaire and structured interview. Multiple logistic regression was used to identify patient characteristics independently predictive of warfarin maintenance requirements >5 mg/d. An assessment tool for estimating an individual patient's likelihood of requiring warfarin maintenance doses >5 mg/d was derived from the logistic regression model and was assessed in both the study cohort and a separate historical validation cohort of 125 patients.
RESULTS: Five factors were independently associated with warfarin requirements >5 mg/d: age <55 years, male gender, African American ethnicity, vitamin K intake >400 micro g/d, and body weight >or=91 kg. The assessment tool derived from these factors correctly classified semiquantitative warfarin requirements as non-high-dose in 84 of 93 study cohort patients and 71 of 78 validation cohort patients, and correctly classified requirements as high-dose in 10 of 13 study cohort patients and 11 of 15 validation cohort patients.
CONCLUSIONS: African American ethnicity is a newly identified predictor of warfarin requirements >5 mg/d and is independent of dietary vitamin K intake. An assessment tool incorporating this and other predictors can estimate a patient's likelihood of requiring such dosages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12243598     DOI: 10.1345/aph.1C025

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  33 in total

1.  Genetic warfarin dosing: tables versus algorithms.

Authors:  Brian S Finkelman; Brian F Gage; Julie A Johnson; Colleen M Brensinger; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

Authors:  M A Perera; E Gamazon; L H Cavallari; S R Patel; S Poindexter; R A Kittles; D Nicolae; N J Cox
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

3.  Treatment of Suspected Pulmonary Embolism in a Super-Obese Individual.

Authors:  Keith Sine
Journal:  Can J Hosp Pharm       Date:  2015 Nov-Dec

4.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Authors:  Nihat Ozer; Nese Cam; Burak Tangurek; Songul Ozer; Huseyin Uyarel; Dilaver Oz; Mehmet Rasit Guney; Figen Ciloglu
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 5.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

6.  Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans.

Authors:  W Hernandez; E R Gamazon; K Aquino-Michaels; S Patel; T J O'Brien; A F Harralson; R A Kittles; A Barbour; M Tuck; S D McIntosh; J N Douglas; D Nicolae; L H Cavallari; M A Perera
Journal:  Pharmacogenomics J       Date:  2013-09-10       Impact factor: 3.550

Review 7.  The future of warfarin pharmacogenetics in under-represented minority groups.

Authors:  Larisa H Cavallari; Minoli A Perera
Journal:  Future Cardiol       Date:  2012-07

Review 8.  Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

Authors:  Aditi Shendre; Chrisly Dillon; Nita A Limdi
Journal:  Pharmacogenomics       Date:  2018-10-22       Impact factor: 2.533

9.  Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Authors:  Aditi Shendre; Gaurav M Parmar; Chrisly Dillon; Timothy Mark Beasley; Nita A Limdi
Journal:  Pharmacotherapy       Date:  2018-02-27       Impact factor: 4.705

10.  Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

Authors:  Wenndy Hernandez; Keston Aquino-Michaels; Katarzyna Drozda; Shitalban Patel; Young Jeong; Harumi Takahashi; Larisa H Cavallari; Minoli A Perera
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.